Allergan, Medytox complete licensing agreement

Allergan has closed a license agreement with Medytox for its neurotoxin product candidates, according to a press release. Allergan will pay Medytox an upfront cash payment of $65 million in exchange for worldwide exclusive rights, outside of Korea, to develop and commercialize certain neurotoxin product candidates currently in development, including a potential liquid-injectable product, the release said.

Full Story →